Deze website maakt gebruik van cookies. We gebruiken cookies om instellingen te onthouden en je bezoek soepeler te laten verlopen. Daarnaast gebruiken we ook cookies voor de verbetering van de website en het verzamelen en analyseren van statistieken. Lees meer over cookies

Home
Marcel Kool

Marcel Kool

Groepsleider

Kool groep

Telefoon 088 97 29 000

E-mail m.kool-5@prinsesmaximacentrum.nl

De novo H3.3K27M-altered diffuse midline glioma in human brainstem organoids to dissect GD2 CAR T cell function
- jan. 2026
- Nils, Bessler, et al
- Nature Cancer
Biglycan-driven risk stratification in ZFTA-RELA fusion supratentorial ependymomas through transcriptome profiling
- dec. 2025
- Konstantin, Okonechnikov, et al
- Acta neuropathologica communications
Correction
- dec. 2025
- Konstantin, Okonechnikov, et al
- Acta neuropathologica communications
High-resolution proteomic analysis of medulloblastoma clinical samples identifies therapy-resistant subgroups and MYC immunohistochemistry as a powerful outcome predictor
- sep. 2025
- Alberto, Delaidelli, et al
- Neuro-Oncology
A cycling, progenitor-like cell population at the base of atypical teratoid rhabdoid tumor subtype differentiation trajectories
- jul. 2025
- Enrique, Blanco-Carmona, et al
- Neuro-Oncology

Bekijk alle publicaties

Marcel Kool

Publicaties

De novo H3.3K27M-altered diffuse midline glioma in human brainstem organoids to dissect GD2 CAR T cell function

Biglycan-driven risk stratification in ZFTA-RELA fusion supratentorial ependymomas through transcriptome profiling

Correction

High-resolution proteomic analysis of medulloblastoma clinical samples identifies therapy-resistant subgroups and MYC immunohistochemistry as a powerful outcome predictor

A cycling, progenitor-like cell population at the base of atypical teratoid rhabdoid tumor subtype differentiation trajectories